Non-Hodgkin Lymphoma — Trials

Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,167
Recruiting: 1,126
Ph III recruiting: 114
Growth YoY: +4%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.5%
Trials / 1,000 deaths: 108.4 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,291)

clinicaltrialsPublishedShowing 851–900 of 2,538 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06723457	Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma	recruiting	Phase 2	34	Reem KarmaliOTHER	1	Jul 8, 2026	clinicaltrials
NCT06854159	Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy	recruiting	Phase 2	34	University of California, DavisOTHER	1	Jul 8, 2026	clinicaltrials